pradigastat

Pradigastat is a potent, selective, orally administered small molecule inhibitor of diacylglycerol acyltransferase 1 (DGAT1), an enzyme that catalyzes the final step in triglyceride synthesis from diacylglycerol and acyl-coenzyme A. By inhibiting DGAT1, pradigastat reduces the formation of triglycerides, particularly in the small intestine, leading to decreased postprandial triglyceride levels. It has been investigated for several metabolic disorders associated with abnormal lipid metabolism including familial chylomicronemia syndrome (FCS), severe hypertriglyceridemia (including familial hyperchylomicronemia phenotypes I and V), non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus, obesity, and constipation. Pradigastat was originally developed by Novartis and later licensed to Anji Pharma for further development[4][5][6][7].

Brand names

pradigastat

Other names

pradigastat sodium